169 results about "Schizophrenia disorder" patented technology

The invention relates to the technical field of trajectory accompanying, in particular to a schizophrenia prediction model construction method based on multi-modal subject data and artificial intelligence, which comprises the following steps: standardizing a prospective queue design and a multi-modal data acquisition protocol; carrying out synchronous acquisition and quality control on multi-modal data; carrying out dimension reduction and cross-modal alignment fusion processing on the data; and combining an improved loss function and a self-adaptive optimization algorithm to train the model, and performing verification and iterative optimization. According to the schizophrenia prediction model construction method based on the multi-modal subject data and the artificial intelligence, multi-modal standardized acquisition is taken as a core, multi-dimensional pathological support is provided for prediction through multi-modal data deep coverage and standardized acquisition, and refined preprocessing is designed for different modals, so that the schizophrenia prediction model construction efficiency is improved. In combination with modal specific feature extraction and cross-modal alignment fusion, a dynamic weighted multi-modal network is matched with multi-task learning and improved AdamW optimization, and in combination with comparison pre-training, characterization capability and training efficiency are improved.

The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and / or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A / D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).

The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

The invention relates to the technical field of psychiatric disease diagnosis, and discloses a defective schizophrenia prediction and analysis system based on multi-modal brain network characteristics, which comprises an image data acquisition module, an image data processing module, a deep learning model module and a prediction module which are connected in sequence, the image data acquisition module acquires a brain MRI image; the image data processing module carries out cortical and subcortical reconstruction on the brain MRI image to obtain a model input index; the deep learning model module performs training by using a training data set composed of a plurality of brain MRI images and defective schizophrenia diagnosis results thereof to obtain a target prediction model; and the prediction module inputs the real-time brain MRI image into the target prediction model to obtain a prediction result. According to the method, the multi-dimensional brain structure image features are integrated, diagnosis information contained in brain region changes is fully mined, prediction results of defective schizophrenia and non-defective schizophrenia are improved, and a more comprehensive biological basis is provided for clinical diagnosis.

The invention provides a metabolic marker for auxiliary diagnosis of schizophrenia, a construction method and application. Wherein the metabolic marker comprises lysophosphatidylcholine (LPC) (17: 0 / 0: 0), oleamide, lysophosphatidyl ethanolamine LysoPE (18: 0 / 0: 0), palmitamide, lysophosphatidyl ethanolamine LysoPE (0: 0 / 20: 4), lysophosphatidyl ethanolamine LysoPE (22: 6 / 0: 0), p-methylphenol sulfate, lactic acid, 3-hydroxybutyric acid, lysophosphatidyl ethanolamine LysoPE (18: 2 / 0: 0), lysophosphatidyl ethanolamine LysoPE (16: 0 / 0: 0) and sphingosine 1-phosphate. By utilizing the metabolic marker, auxiliary diagnosis of schizophrenia can be rapidly and accurately completed in the early stage of disease attack.

The present application relates to the technical field of data analysis, and discloses an auxiliary identification method, device and equipment for early schizophrenia and a storage medium, which are used to improve the auxiliary identification accuracy of schizophrenia. The auxiliary identification method for early schizophrenia comprises: classifying multidimensional data of a target individual, including a topology structure type, a sequence type and a type without special structure; using a graph neural network, a recurrent neural network and a convolutional neural network to extract feature information of the three types of data respectively; fusing the feature information to form a target vector; processing the target vector through a preset early schizophrenia identification model to obtain an identification result, so as to determine the risk degree of the target individual in the early stage of schizophrenia.

Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

The invention discloses an AI-based schizophrenia clinical thinking training simulation system, which relates to the technical field of artificial intelligence, and is characterized by comprising the steps of constructing a dynamic knowledge base, receiving and preprocessing multi-modal input, performing standardized mapping by extracting keywords, and then performing judgment of a rule layer and a semantic layer. A student question method and a standard answer method in the dynamic knowledge base are sent into a model for response generation, then four-dimensional quantitative scoring and clinical operation multi-dimensional scoring are carried out, error codes and positioning sentences thereof are output, and finally personalized training courses are recommended to students; and hot-updating the dynamic knowledge base continuous optimization model. According to the method, four dimensions of the ICD-10 diagnostic standard are converted into a quantitative scoring algorithm capable of being automatically executed, quantitative assessment of clinical operation specifications is integrated, a diagnosis and operation double-track evaluation system is constructed, the problems that a traditional method is lack of evaluation standards and high in subjectivity are solved, and the evaluation efficiency is improved. Therefore, the evaluation of the clinical thinking ability of the medical students becomes objective, comprehensive and evidence-based.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

This invention discloses a multi-task behavioral-EEG synchronous monitoring method for schizophrenia screening, relating to the field of schizophrenia screening. The method includes: designing a multi-task temporal loading paradigm based on clinical screening needs; simultaneously collecting EEG signals and behavioral data of subjects during the execution of the multi-task temporal loading paradigm, and preprocessing the collected raw data; extracting multidimensional features from the preprocessed data, wherein the multidimensional features include EEG feature groups, behavioral feature groups, and time-varying feature groups; constructing a multimodal fusion discriminant model, inputting the multidimensional features into the multimodal fusion discriminant model, and outputting a baseline risk probability and a schizophrenia risk index. The advantages of this invention are: achieving efficient, accurate, and objective screening of the core cognitive dimensions of schizophrenia, effectively improving the sensitivity and specificity of screening.

The invention discloses a schizophrenia concurrent metabolic syndrome independent risk factor screening method and system, utilizes a binary logistic regression analysis method to analyze relevance between multi-source factors and concurrent MetS and screen out independent risk factors, and relates to the technical field of medical data processing. According to the schizophrenia concurrent metabolic syndrome independent risk factor screening method and system, the relevance between multi-source factors and concurrent MetS is analyzed through a binary logistic regression analysis method, the independent risk factors are screened out, and a decision tree model is constructed based on the reserved independent risk factors and used for visually displaying and predicting the risk of concurrent MetS of a patient. By comprehensively considering multi-aspect information of the schizophrenia patient and adopting independent risk factor determination and model construction operation, the independent risk factors causing MetS occurrence of the schizophrenia patient are accurately identified, the screening accuracy is improved, meanwhile, the level of MetS concurrent by the patient is predicted, subsequent clinical timely intervention is facilitated, and the risk of MetS occurrence of the schizophrenia patient is reduced. And the MetS concurrent probability of the patient is reduced.

This invention relates to the field of pharmaceutical technology, and discovers that the natural products boldinine and norboldinine can be used as NTSR1 (Neurotensin receptor-1, NTSR1) receptor antagonists and their applications. The compounds are boldinine and norboldinine ((+)-Laurolitsine), which have NTSR1 receptor antagonistic activity and are NTSR1 receptor antagonists that can prevent and treat alcohol poisoning, addiction, schizophrenia, autism spectrum disorder, and mood disorders. Accordingly, this invention can provide novel NTSR1 receptor antagonist prospective compounds with clear targets for the above-mentioned related diseases.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and / or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit / Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

A method includes, for each corresponding electrode of one or more electrodes attached to a head of a patient, receiving corresponding electrical activity data representing neural activity within a corresponding area of a brain of the patient based on corresponding electrical activity measured by the corresponding electrode. The method also includes receiving stimulation data representing a plurality of stimulation times each corresponding to a stimulation applied to the patient while the one or more electrodes are attached to the head of the patient, and processing the corresponding electrical activity data and the stimulation data to determine a modulation depth for the patient. The method also includes assessing, based on the modulation depth, cognitive impairment of the patient due to a diagnosis of schizophrenia.

The present disclosure relates to the novel use of ANAVEX3-71 and related compounds in medical treatments, such as Parkinson's Disease, Frontotemporal Dementia, Schizophrenia, and Alzheimer's Disease.

The invention discloses a dynamic monitoring method and system for urban young adults schizophrenia, and relates to the technical field of artificial intelligence, and the method comprises the steps: dividing urban young adults whose schizophrenia recognition results are schizophrenia into urban young adults people with schizophrenia; constructing a schizophrenia index library based on the detectable data, the preventive data, the manageable data and the treatable data; in response to an information acquisition request of a to-be-tested patient, acquiring to-be-tested patient information, and determining attributes of the to-be-tested patient based on the to-be-tested patient information; setting attention index item labels for the to-be-tested patients according to the attributes of the to-be-tested patients, and searching one or more attention index items corresponding to the attention index item labels from a schizophrenia index library; and binding the searched one or more attention index items with the attributes of the to-be-tested patient to form an attention index item analysis report corresponding to the to-be-tested patient, thereby being beneficial to solving the problem that dynamic monitoring of urban young schizophrenia cannot be realized in the prior art.

A method is provided to bring about the necessary improvement in the user's empirical negative symptoms of schizophrenia. The calculation system can obtain a first metric associated with the user from multiple point in time. The calculation system can repeat the operation of identifying a configuration file selected based on the endpoint for improving empirical negative symptoms from multiple point in time. The calculation system can repeatedly present a set of content items identified by the configuration file to encourage the user to perform activities toward achieving the endpoint. The calculation system can obtain a second metric associated with the user from multiple point in time. If the second metric is lower than the first metric, the user is considered to have improved in the empirical negative symptoms of schizophrenia. The calculation system can enhance the effectiveness of medications the user is taking to cope with schizophrenia.

The invention relates to the technical field of traditional Chinese medicines, relates to new application of a traditional Chinese medicine composition, and in particular relates to application of the traditional Chinese medicine composition in preparation of a medicine for preventing and / or schizophrenia. The traditional Chinese medicine composition is prepared from cassia twig, white peony root, honey-fried licorice root, ginger, jujube, ginseng, Chinese angelica, salted morinda officinalis and dwarf lilyturf tuber. The composition disclosed by the invention can be used for remarkably inhibiting impairment of social competence of schizophrenia mice and abnormal increase of glutamic acid concentration of prefrontal cortex, and has a relatively good treatment effect on the schizophrenia mice.

Disclosed are compounds of formula (I) wherein G1 is as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in the treatment of e.g. a neurodegenerative disorder, a movement disorder, or a brain disorder, such as e.g. Parkinson's disease, drug-induced Parkinsonism, dystonia, Tourette's syndrome, dyskinesias, schizophrenia, cognitive deficits associated with schizophrenia, excessive daytime sleepiness, attention deficit hyperactivity disorder (ADHD), Huntington's disease, chorea, cerebral palsy, and progressive supranuclear palsy. An exemplary compound is e.g. (2,5-difluoro-4-(6-(((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-λ6-sulfanone (e.g. example 12; compound no. 7) Pharmacological data on the activity of the compounds in an mAChR M4 cell-based assay are provided (e.g. table 2).TABLE 2Human M4Cpd. No.IC50 (nM)Emin (%)*113.44239.62318.5345846575.4361883746.0385607918.43101.821186.231243.42138.63*% ACh maximum at 30 μM.

The present invention relates to novel compounds of Formula (I'), wherein P, Q, A, B, m, n, R1, R2, R9, R10, R11 and R12 are defined as in Formula (I'). These compounds may be useful as muscarinic M4 receptor subtype ("M4-mAChR") positive allosteric modulators which are useful for the treatment or prevention of neurological and psychiatric disorders associated with muscarinic M4 receptor dysfunction and diseases in which the M4 receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other disorders modulated by M4 muscarinic receptors.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Novel compositions of N-desmethyl ruboxistaurin L-lactate salt and L-lactate salt polymorphs. The use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in the treatment of subjects having a neurological disease and / or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs administered in combination with lithium or other treatments for bipolar disorder are also disclosed.

A kind of schizophrenia electroencephalogram data recognition method based on pulse neural network, collects the electroencephalogram data of schizophrenia patient and healthy control person;The original data are pretreated;Including signal filtering, artifact removal, signal segmentation and data standardization;Extract multi-scale space-time feature, including time-frequency feature, functional connection feature and spatial feature;Including time-frequency feature extraction, functional connection feature extraction and feature fusion three steps;Three-layer pulse neural network is constructed, including input layer, hidden layer and output layer;The connection model between brain partition based on pulse neural network is constructed;Improved back propagation algorithm is used to train network;The difference of brain partition connection mode of schizophrenia patient and healthy person is analyzed.The present application constructs the brain partition connection model of signal distinction of schizophrenia patient and healthy person by simulating the dynamic activity of brain neuron, realizes the improvement of schizophrenia classification accuracy.

The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.

The present invention relates to a nitrogen-containing heteropolycyclic derivative modulator, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a modulator in the preparation of drugs for treating menopausal syndrome, polycystic ovarian syndrome, uterine fibroids, schizophrenia, irritable bowel syndrome, vasomotor symptoms, breast cancer and related disorders thereof, wherein each substituent in general formula (I) is the same as defined in the description.

The invention discloses a heteroaromatic compound as well as a preparation method and application thereof. The invention provides a compound as shown in a formula I, and a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. The novel aromatic heterocyclic compound is a selective dopamine D1 / D5 ligand, has good affinity and selectivity to a target spot, and can be used for treating D1 / D5-mediated (or D1 / D5-related) disorders including schizophrenia, cognitive impairment, age-related cognitive decline, dementia, Parkinson's disease and the like.

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and / or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

The application belongs to the technical field of medicines, and relates to an N-H aporphine nitrogen-containing heterocyclic derivative, a preparation method and application thereof.The N-H aporphine nitrogen-containing heterocyclic derivative comprises a compound shown in a general formula M, isomers thereof and pharmaceutically acceptable salts or hydrates thereof.The application introduces a nitrogen-containing heterocyclic ring into an aporphine derivative, and the disclosed N-H aporphine nitrogen-containing heterocyclic derivative can be applied in the preparation of medicines for preventing and / or treating obesity, urinary incontinence, depression, anxiety, obsessive-compulsive disorder, epilepsy, schizophrenia, pain, diabetes and drug addiction.

This invention provides in some aspects, combinations, compositions and kits comprising a psychedelic drug and an NMD A receptor agonist and applications and uses of same for treating, reducing the incidence of, reducing the severity of or improving a pathology of a subject with a neurologic disease or disorder, a neurocognitive disease or disorder, or a motor disease or disorder, or for enhancing neuroplasticity in a subject with a neurologic disease or disorder, a neurocognitive disease or disorder, or a motor disease or disorder making use of the combinations, compositions and kits of this invention.